ArticleJournal of clinical apheresis2025
Refinement of Replacement Fluid Using Human Serum Albumin Preparation to Enhance Biocompatibility in Therapeutic Plasma Exchange.
Article in Journal of clinical apheresis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refinement of Replacement Fluid Using Human Serum Albumin Preparation to Enhance Biocompatibility in Therapeutic Plasma Exchange.Journal of clinical apheresis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human serum albumin (HSA) solution is widely used as a replacement fluid during therapeutic plasma exchange (TPE). However, the ionic concentrations in commercially available 5% HSA solutions differ significantly from physiological levels. In this study, we developed a simple method for preparing a replacement fluid with ion concentrations closer to physiological norms by mixing 25% HSA with lactated Ringer's solution, sodium chloride, and calcium gluconate hydrate. We prepared three types of replacement fluids, each with a 4.0% albumin concentration and total volumes of 1.83, 2.43, and 3.04 L, and confirmed their compositional stability for up to 48 h. Compared with the standard 5% HSA solution, the prepared fluids had calcium, sodium, potassium, and chloride levels more closely aligned with physiological values. Using HSA-based replacement fluids with preadjusted electrolyte concentrations may help reduce the risk of imbalances, such as hypocalcemia, during TPE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.